Allergan confirmed that it had received the meeting requests, saying it will review them with an independent inspector and "expects to report the results promptly following this review." The company said "many stockholders have explicitly conveyed their view" that calling for a meeting is "not an endorsement of Valeant's offer." The offer is "grossly inadequate," but the board of directors "fully supports the right of stockholders to vote on the value proposition offered by Valeant at the appropriate time," Allergan said.